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Introduction: Steroid withdrawal in renal transplantation is desirable to avoid their adverse
effects. However, by decreasing the immunosuppression, could lead to an increased risk for
the  development of HLA-Abs.
Objective: Evaluate the relationship between steroid withdrawal and development of HLA-
Abs  in renal transplantation.
Methods: We  analyzed sera by Luminex from 182 kidney transplants performed from 1998
to  2011, before and two years after transplantation. All the patients had a pretransplant
PRA  (panel reactive of antibodies) <20% by complement-dependent cytotoxicity (CDC) and
maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF). We
compared a group of steroid withdrawal at 7 months (group-I; n = 130) and another control
with non-withdrawal (group-II; n = 52).
Results: 22 patients (16.9%) in group-I and 11 patients in group-II (21.1%) had HLA-Abs after
two  years (pNS). Despite excluding patients with PRA >20%, we detected HLA-Abs pretrans-
plant by Luminex in 11.5% of patients in both groups, of which, 66.6%, versus 53% (p 0.058),
developed new speciﬁcities, with a similar percentage of donor speciﬁc antibodies (DSA) in
both groups (33.33% vs 36.36%), pNS. In the subgroup without pretransplant HLA-Abs (group-
I;  n = 115, group-II; n = 45), 6.08% developed de novo HLA-Abs, being DSA 3.4% (Group-I) versus
7.69% in group II with 3.84% DSA (pNS).
Conclusions: Steroid withdrawal at 7 months of renal transplantation does not entail a higher
risk  in terms of HLA-Abs development in patients without pretransplant HLA-Abs and
treatment with tacrolimus and MMF, although larger studies are needed to conﬁrm these
ﬁndings.©  2017 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
∗ Corresponding author.
E-mail address: elenamonfa@gmail.com (E. Monfá).
ttp://dx.doi.org/10.1016/j.nefro.2017.02.002
211-6995/© 2017 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introducción: La retirada de esteroides en el trasplante renal es deseable por sus efectos
adversos, sin embargo, al disminuir la inmunosupresión podría conllevar un riesgo superior
para el desarrollo de Ac-anti-HLA.
Objetivo: Evaluar la relación entre la retirada de esteroides y el desarrollo de Ac-anti-HLA en
el  trasplante renal.
Métodos: Se evaluaron los sueros por Luminex de 182 trasplantados renales desde 1998 a
2011,  antes y a los 2 an˜os del trasplante. Todos tenían un panel reactivo frente a anticuerpos
(PRA) < 20% pretrasplante por citotoxicidad dependiente de complemento y mantuvieron la
inmunosupresión con tacrolimús y micofenolato mofetilo (MMF). Comparamos un grupo de
retirada de esteroides a los 7 meses (grupo i; n = 130) y otro de no retirada (grupo ii; n = 52).
Resultados: 22 pacientes (16,9%) en el grupo i y 11 pacientes en el grupo ii (21,1%) presentaban
Ac-anti-HLA a los 2 an˜os (pNS). A pesar de excluir a los pacientes con PRA > 20%, detectamos
Ac-anti-HLA pretrasplante por Luminex en el 11,5% de los pacientes en ambos grupos, de
los cuale, desarrollaron nuevas especiﬁcidades el 66,6% del grupo i y el 53% en el grupo
ii  (p 0,058), con un similar porcentaje de anticuerpos donante especíﬁcos (DSA) (33,3% vs.
36,36%), pNS. En el subgrupo sin Ac-anti-HLA pretrasplante (grupo i; n = 115; grupo ii; n = 45),
el  6,08% desarrollaron Ac-anti-HLA de novo, siendo DSA el 3,4% (grupo-I) vs. 7,69% con DSA
en  el 3,84% (grupo-II), pNS.
Conclusiones: La retirada de esteroides a los 7 meses del trasplante renal no conlleva un riesgo
superior en términos de desarrollo de Ac-anti-HLA en aquellos pacientes sin anticuerpos
pretrasplante y en tratamiento con tacrolimús y MMF, aunque se requieren estudios más
amplios para conﬁrmar estos hallazgos.
© 2017 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
The detection of antibodies against the HLA system (HLA-
Abs) in transplantation has been linked to the development
of acute and chronic antibody mediated rejection (ABMR)1 in
clinical and subclinical forms of presentation, and remains
as a major cause of graft losses.2 Monitoring HLA-Abs has
become a routine practice in the clinical follow up of renal
transplant recipients3 that helps to indicate a graft biopsy and
early treatment.
The development of de novo HLA-Abs is usually associated
with modiﬁcations in the immunosuppressive treatment. In
clinical practice, the modulation of the immunosuppressive
regimen is common in order to avoid the long-term adverse
effects. The calcineurin inhibitors (CNI) withdrawal or con-
version to mTOR-inhibitor is currently performed to reduce
nephrotoxicity or risk of malignancy.4,5 These changes in
immunosuppression are risk of development of new HLA-Abs
and consequently ABMR.6,7
The steroids withdrawal is also desirable to avoid their
adverse effects on long-term treatment, but its relationship
with the development of new HLA-Abs is not yet well estab-
lished.
One of the most important adverse effects of steroids
is increased cardiovascular risk. The steroid maintenance
has been linked to the onset of diabetes mellitus, dyslipi-
demia, hypertension and obesity.8,9 In a study involving 68,781by-nc-nd/4.0/).
patients who received prednisone versus 82,200 patients who
did not, it was observed that the patients who received doses
of prednisone ≥7.5 mg/day had a relative risk of 2.5 for car-
diovascular events.10 In addition, the rate of death with a
functioning graft is high (40%) being cardiovascular events the
most frequent cause.11 Therefore, the maintenance of steroids
could be a modiﬁable cause of death with a functioning graft.
Currently, there are potent immunosuppressants in main-
tenance therapy (Tacrolimus and Mycophenolic mofetil-MMF)
and the steroids withdrawal seems plausible, at least in those
patients with low immunological risk. Steroids withdrawal
has risk of acute rejection and higher slope of glomerular ﬁl-
tration rate (GFR) loss in the long term. We  hypothesize that
steroids elimination can contribute to production of donor
speciﬁc antibodies (DSA). So, the aim of our study is to assess
the relationship between steroid withdrawal and development
of HLA-Abs after renal transplantation.
Material  and  methods
Patients
We studied 652 kidney transplant recipients, performed in
University Hospital Marqués de Valdecilla, Santander (Spain)
from January 1998 to December 2011 who met  the following
criteria: graft survival of at least two years and maintenance
of immunosuppression with tacrolimus and MMF  during the
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Table 1 – Demographic, immunologic and clinical parameters of the patients included in the study (Group I: steroid
withdrawal; Group II: non steroid withdrawal).
Group I (n = 130) Group II
(n = 52)
p
Age (years ± SD) 53.7 ± 11.8 45.1 ± 11.6 <0.05
Gender (% male) 70  73 NS
Dyalisis time (months: median, range) 13.17
(9.3–26.2)
17.16
(9.6–28.5)
NS
HLA mismatches 4–6 (%) 65.4 54.6 NS
PRA pre-Tx (<10%/≥10%) 128/2 56/1 NS
Retrasplant 28 (21%) 13 (25%) NS
Cold ischaemia time (hours ± SD) 18.7 ± 6.3 18.3 ± 6.6 NS
Transplantion before 2003 4 (3%) 32 (61.5%) <0.05
Induction with thymoglobulin 0 0 NS
Induction with basiliximab 30 (23.1%) 7 (13.4%) NS
Donor type (deceased/living) 125/5 51/1 NS
Acute rejection < 7 months after transplantation 15 (11.5%) 8 (15.3%) NS
Acute cellular rejection ≥ Ib (<7 months) 7 (5.3%) 6 (11.5%) NS
Acute rejection >7 months 2 (1.5%) 0 NS
ﬁ
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Acute antibody-mediated rejection < 24 months 0 
rst two years after transplantation. We  excluded of the
tudy: combined transplants; retransplants which lost the ﬁrst
ransplant for rejection; panel reactive of antibodies (PRA)
retransplant >20% by complement-dependent cytotoxicity
CDC), acute antibody-mediated rejection (ABMR) during the
 months after transplantation. Finally, 182 kidney transplant
ecipients fulﬁlled the inclusion criteria and were included in
he study.
The patient data were obtained from the prospectively
aintained database of renal transplant patients at our cen-
re. The demographic, immunologic and clinical parameters
re summarized in Table 1. Patients were classiﬁed into two
roups according to steroid withdrawal: Group-I: removal of
teroids at 7 months posttransplant (n = 130) and Group-II:
teroids maintenance during the ﬁrst two years after trans-
lantation (n = 52).
Both groups were comparable in terms of gender, time on
ialysis, retransplants, cold ischaemia time, HLA mismatches,
retransplant sensitization (tested by CDC), induction therapy
ith thymoglobulin or basiliximab, and acute rejection during
he 7 months after transplantation. The Group II patients were
igniﬁcantly younger and predominate transplants before
003, as the only statistically signiﬁcant differences. The mean
tudy follow-up was two years after transplantation.
teroid  withdrawal  protocol
n 2003, we  started a protocol with steroid withdrawal up
o 7 months after kidney transplantation in patients treated
ith tacrolimus and MMF,  and excluding those patients with
igh immunological risk (acute ABMR; acute cellular rejection
ith a degree > Ib of the Banff classiﬁcation in the 7 months
fter transplantation, pretransplant PRA > 20% or rejection
ith graft loss in prior transplants). However, even before 2003,n some patients, steroids were withdrawn at 7 months with
he same criteria.
An earlier withdrawal was not performed at our centre
ecause we  do not use induction thymoglobuline routinely,0 NS
0 NS
and decided to make a slow pattern of steroids that ended at
7 months.
The prednisone dose reduction consisted in gradually
decreasing the dose until the complete withdrawal up to 7
months after transplantation: 15 mg/d at 15 days; 10 mg/d a
day at one month; 7.5 mg/d at two months; 5 mg/d at three
months; 5 mg/d and 2.5 mg/d alternating at four months;
2.5 mg/d at ﬁve months; 2.5 mg every other day at six months
until complete withdrawal at seven months.
Serum  samples  selection  and  sera  analysis
Serum samples of all transplanted patients were routinely
collected and stored at −80 ◦C. Frozen serum samples were
selected to investigate the presence of HLA-Abs. For every
patient, two samples were selected, one immediately before
transplantation and another one two years after transplan-
tation. The sera were analyzed by LABScreen®Mixed (One
Lambda Inc., Canoga Park, CA, USA) for screening antibodies
and LABScreen®Single antiHLA Antigen (One Lambda) class-I
and/or class-II if were positive in the screening. A total of 372
serum samples were analyzed.
A mean ﬂuorescence intensity (MFI) value greater than
1500 was considered positive for a particular HLA speciﬁcity.
Statistical  methods
Quantitative variables were compared using the t-Student’s
test. The percentages were obtained with the chi-square test.
Differences were considered signiﬁcant when p-value was
below 0.05.
Results
Twenty-two patients (16.92%) in group I and eleven patients
(21.15%), in Group II (pNS) presented serum HLA-Abs at two
years after transplantation (Table 2).
When pretransplant sera were analyzed by Luminex a total
of ﬁfteen patients (11.53%) in steroid withdrawal group, and
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Table 2 – List of speciﬁcities HLA-Abs detected pretransplant and posttransplant. DSA with the MFI value.
Case Class-I
speciﬁcities
pre-Tx
Class-I
speciﬁcities
at  two years
after Tx
Class-II
speciﬁcities
pre-Tx
Class-II
speciﬁcities
at  two years
after Tx
DSA  MFI
DSA post-Tx
Group I
1 NDSA NNDSA NDSA DSA (DR7) + NDSA DR7 4080
2 NDSA NNDSA NDSA DSA (DR52) + NNDSA DR52 9836
3 NDSA NNDSA NDSA DSA (DQ4) + NNDSA DQ4
(associated to
DR8)
4887
4 NDSA NN NDSA DSA (DR51) + NNDSA DR51 8270
5 – – – DSA (DR7) DR7 3518
6 – DSA (B44) – – B44 3782
7 – NDSA
Cw6, Cw15
Cw17, Cw18
– DSA (DR53) + NDSA NAa
DR53
2724
8 – – NDSA DSA (DR15) + NNDSA DR15 15,989
9 – – – DSA (DR53) + NNDSA DR 53 4080
10 – NDSA
Cw1, Cw2
Cw4, Cw5
Cw6, Cw7
Cw8, Cw9
Cw10, Cw12
Cw14, Cw15
Cw16, Cw17
Cw18
–  – NAa
11 – – – NDSA
12 NDSA NN – –
13 NDSA NN – –
14 – – NDSA NN
15 NDSA NNDSA
Cw15
–  – NAa
16 NDSA NN NDSA NN
17 – – NDSA NNDSA
18 – – NDSA NN
19 – Cw 15 – – NAa
20 – – NDSA DP14 NAb
21 NDSA NNDSA – –
22 NDSA NNDSA – –
Group II
1 NDSA – NDSA DSA (DR53) + NNDSA DR53 11,371
2 NDSA NN NDSA DSA (DR8) + NNDSA DR8 2368
3 – DSA (A2,
A29) + NDSA
–  NDSA A2 3567
A29 2497
4 NDSA NN NDSA DSA (DR4) + NNDSA DR4 4613
5 NDSA NN NDSA NN –
6 NDSA NN – –
7 NDSA NNDSA NDSA
DP1, DP20,
DP23,
DPA1*02:01
DPA1*04:01
DP13 NAb
8 – – NDSA NN
9 – – – NDSA
10 – – NDSA NN
11 – Cw4 – – NAa
DSA: donor speciﬁc antibodies; NDSA: not donor speciﬁc antibodies; NNDSA: new not donor speciﬁc antibodies; NN: not new speciﬁcities; MFI:
mean ﬂuorescence intensity; Tx: transplantation.
a NA: not available due to lack of C-locus typing.
b NA: not available due to lack of DP-locus typing.
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Table 3 – Patients with HLA-Abs pretransplant, and differentiation according to the speciﬁcities observed after two years
of transplantation.
Group I
(n = 130)
Group  II
(n = 52)
p
HLA Abs pre-Tx 15 (11.53%) 6 (11.53%) NS
NN 5 (33.33%) 2 (33.33%) NS
NDSA 5 (33.33%) 1 (16.66%) NS
DSA 5 (33.33%) 3 (36.36%) NS
NN: not new speciﬁcities; NDSA: not donor speciﬁc antibodies; DSA: donor speciﬁc antibodies.
Table 4 – Patients without HLA-Abs before transpantation and the HLA-Abs at two years after transplantion.
Group I
(n = 115)
Group II
(n = 45)
p
Patients
(HLA-Abs negative
pre-Tx, positive at two
years)
7(6.08%)  4 (7.69%) NS
NDSA de novo 3 (2.61%) 2 (3.84%) NS
De no
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ADSA de novo 4 (3.47%) 
NDSA: not donor speciﬁc antibodies; DSA: donor speciﬁc antibodies; 
ix patients (11.53%) in the group of steroid maintenance
resented HLA-Abs prior kidney transplantation, despite the
xclusion criteria of PRA > 20% by CDC. Of these patients, ten
eveloped new speciﬁcities after two years (66.66%) from the
roup I, versus four patients (53.02%) from the group II (p 0.058),
ith a similar percentage of DSA (33.33% in group I vs 36.36%
n group II) (Table 3).
Within the patients without HLA-Abs before kidney trans-
lantation (group I-n = 115; group II-n = 45), seven patients in
652 kidney transplant
recipients
182 kidney transplant
recipients
130 steroid withdrawal-Group I
15 +
HLA-Abs
7 +
HLA-Abs
10 new
specificities
HLA-Abs 5 DSA 4 DSA
115 –
HLA-Abs
ig. 1 – Study design and description of patients with pretranspl
idney transplantation. PRA, panel reactive antibodies; CDC com
BMR, antibody-mediated rejection.2 (3.84%) NS
vo:  speciﬁcities with new development; Tx: transplantation.
steroid withdrawal group (6.08%) developed de novo HLA-Abs,
four of them being DSA (3.47%) whereas four patients in the
group II (7.69%) developed de novo HLA-Abs and two of them
were DSA (3.84%); pNS (Table 4). Therefore, in the subgroup
without preformed antibodies, there are not differences in
the development of antibodies in both groups (6.08% vs 7.69%,
pNS), although steroid withdrawal (Fig. 1).
Only two patients (1.5%) in group I had acute cellular rejec-
tion after steroid withdrawal, with grades Ia and Ib of Banff
4 new
specificities
HLA-Abs 3 DSA 2 DSA
4 +
HLA-Abs
6 +
HLA-Abs
46 –
HLA-Abs
Pre-Tx
2 years
after Tx
52 steroid manteinance-Group II
Sera
analised by
luminex
Inclusion criteria:
-Graft survival and maintenance
of tacrolimus and MMF during
the first two years after
transplantation.
Exclusion criteria:
-Combined transplant
-Retransplant due to rejection
-PRA >20% pre-tx by CDC
-ABMR during first 7m after Tx
ant HLA-Abs and development HLA-Abs at 2 years after
plement-dependent citotoxicity; Tx, transplantation;
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Fig. 2 – Comparison of graft survival in both groups. Group
I: steroids withdrawal, Group II: steroids maintenance. Log
1.0
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Fig. 3 – Comparison of graft survival between patients who
had HLA-Abs at two years of transplantation (Group B) whorank: p = 0.432.
classiﬁcation. The last one had already pretransplant HLA-
Abs, and developing a DSA (DQ4) at two years. The other did
not develop HLA-Abs. None of recipients in both groups had
ABMR during the study period.
In terms of graft survival, no statistically signiﬁcant differ-
ences in both groups (Fig. 2) are appreciated, however those
patients with HLA-Abs at two years after transplantation have
worse survival (Fig. 3 and Table 5). The inﬂuence of HLA
Abs is conﬁrmed in graft survival, after multivariate analysis
(p < 0.001 and HR 2.758, 95% CI 1597–4764).
Discussion
The minimization of immunosuppression could increase the
risk of HLA-Abs development as previously demonstrated in
CNI conversion to imTOR.6,7 Steroids withdrawal are not been
studied in relation to the development of DSA in organ trans-
plantation. The huge advantages of steroids elimination in
relation to metabolic and cardiovascular adverse events may
not be sufﬁcient if a signiﬁcant immunological risk is demon-
strated.
There is only one study that analyzes the production of
HLA-Abs in kidney transplants in adults, after early steroid
withdrawal (7 days post-transplant). They concluded that
steroid withdrawal at 7 days posttransplant was not at higher
risk for developing HLA antibodies, but all patients have
received induction with thymoglobuline.12 Our study is the
Table 5 – Graft survival according to steroids withdrawal/maint
transplantation.
Graft survival n 
Group I-steroids withdrawal 130 
Group II-steroids maintenance 52 
HLA-Abs positive at two years 34 
HLA-Abs negative at two years 148 did not have HLA-abs at two years. Log Rank: p < 0.001.
ﬁrst to assess the relationship between intermediate steroid
withdrawal and the detection of serum HLA-Abs in renal
transplants with standard immunosuppression (tacrolimus
and MMF).
Our data suggest that steroid withdrawal up to 7 months
after transplantation does not imply a higher risk of HLA-Abs
development in patients with low immunological risk, and,
more speciﬁcally, in patients who do not have HLA-Abs before
transplantation. On the contrary, in patients with preformed
HLA-Abs, the frequency of new HLA-Abs after steroid with-
drawal increased (66.66%) as compared with non-withdrawal
group (53.02%; p 0.058). Although there is no statistically sig-
niﬁcant difference, a higher tendency is observed in the group
of steroid withdrawal, but further study is needed to conﬁrm
this point. This is in agreement with previous results from
our group in kidney recipients converted from CNI  therapy to
mTORi therapy.7
The primary goal of the study was to observe the develop-
ment of HLA-Abs after steroid withdrawal, not to assess the
effect on rejection or graft survival. However, we  have analyzed
graft survival, detecting worse survival in those with anti-
HLA antibodies. We have found no differences between the
Group I and II. In the study period, only two patients in group
I (1.5%) had a acute cellular rejection after steroid withdrawal.
There are well-designed studies addressing this point. In a
meta-analysis, Knight et al.13 observed that the acute rejec-
tion rate was slightly higher in the group of steroid withdrawal,
enance and presence of HLA-Abs at two years after
At 5 years At 10 years
86.9% 68.6%
86.5% 60.7%
73.5% 33%
89.9% 73%
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ut most of it of low-grade (class I-Banff classiﬁcation). This
roup also showed a tendency to increase the rate of graft loss
ensored death. This trend disappears when all graft losses
re included, including death with a functioning graft. Such
ata probably reﬂect the beneﬁt on patient survival by remov-
ng the steroids to reduce cardiovascular risk. The studies
ncluded in the meta-analysis presented different moments
f withdrawal, from the ﬁrst day after transplantation up to
4 months after transplantation. In contrast, Opelz et al.,14
n a prospective study following 7 years after transplantation,
ompared a group with steroid withdrawal not earlier than
 months after transplantation (1100 patients), and a con-
rol group with steroids maintenance (3045 patients). They
bserved beneﬁts in the group that had undergone steroid
ithdrawal in terms of graft survival, patient survival, graft
urvival censoring death, and improvement in cardiovascular
isk factors. They detected no difference in the rate of acute
ejection or dysfunction renal in both groups, unlike other
tudies (with fewer patients) in which the steroid withdrawal
as earlier and more  acute rejection rate.15
Currently, there is no universal steroid withdrawal proto-
ol. In accordance with the study of Opelz et al., it seems safe
nough to remove steroids after 6–7 months of transplanta-
ion, as we followed in our protocol.
The present study has a number of limitations. First of all,
t is an observational study. Although the steroid withdrawal
rotocol at 7 months after transplantation in patients with
ow immunological risk was established in 2003, it was not
niversally applied to all patients. Nonetheless, between 1998
nd 2003, some patients had a steroid withdrawal at 7 months
t our centre. This has allowed us to have a time-matched
roup in steroids maintenance. The withdrawal protocol was
ollowed by patients without acute rejection ≥ Ib of Banff
lassiﬁcation, however a small percentage of patients (5.3%)
ith such rejection grades were removed from steroids at
 months, only one of them developed DSA, but he had
reformed antibodies, and the remaining patients did not
evelop antibodies. In the group with steroids maintenance,
he frequency of patients with acute cellular rejection ≥ Ib
as higher (11.5%), and this is one reason why steroids were
ept. None of these patients developed antibodies at two
ears.
We also observed that patients from the steroids with-
rawal group were older. It is another limitation of a
etrospective study difﬁcult to avoid since patients were
ollow-up by different nephrologist and some of them decided
ot to withdraw steroids in younger patients because of
he risk of an immunological event and good cardiovascular
roﬁle. In older patients, who  already had impaired fasting
lucose, worse control of blood pressure, dyslipidemia, osteo-
orosis, etc., the decision of steroids withdrawal was easier to
ake.
It can be argued that transplants were performed pre-
ominantly before 2003 in the group II. We have included all
ransplant patients who met  the rigorous inclusion criteria
especially the maintenance tacrolimus and MMF  during the
wo years of study) of our centre from 1998 to 2011. The proto-
ol steroid withdrawal began in our hospital in 2003, however,
t was not applied universally to all patients, for several rea-
ons: acute cellular rejection ≥ IB before 7 months and the(4):415–422 421
presence of several physicians in kidney transplant consul-
tation (refer to the discussion in the previous paragraph). As
this group was not broad enough for a non-steroid withdrawal,
we extended the study until 1998. During that period, there
were patients who had been withdrawn from steroids before
7 months of treatment. This allowed us to have a group of
maintenance steroids comparable in time.
Another limitation is the limited sample size, which does
not allow reach statistically signiﬁcant differences. Larger
studies with more  statistical power are needed to conﬁrm the
results.
The inclusion criteria based on the PRA by CDC is another
limitation. We  detected an increased sensitization level of
patients pretransplant by using a more  sensitive diagnostic
method (Luminex), with a slight tendency towards a higher
percentage in group II. We decided not to discard them from
the analysis, and to study the effect in these subgroups,
although again there were signiﬁcant differences. When we
remove these highly sensitized patients from the study, we
observed that the rate of development of HLA-Abs was simi-
lar in both groups, making this an important ﬁnding from our
study.
In conclusion, steroids withdrawal can be carried out
safely in terms of HLA-Abs production in those recipients
without pretransplant antibodies and under treatment with
tacrolimus and MMF.  The use of new and more  sensitive
methods to measure HLA-Abs makes possible to better select
patients as candidates for steroids withdrawal.
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